DNA
DNA
US37611X2099
Ginkgo Bioworks Holdings, Inc.
Loading chart...

Company Profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Latest News

Related stocks

JBIO
JBIO • United States
Jade Biosciences, Inc.
14.39 USD
915.17M USD 1Y +55.8%
ODTX
ODTX • United States
Odyssey Therapeutics, Inc.
19 USD
913.11M USD
SGP
SGP • United States
SpyGlass Pharma, Inc.
24.92 USD
833.52M USD
SPTX
SPTX • United States
Seaport Therapeutics, Inc.
18.15 USD
971.58M USD
AKTS
AKTS • United States
Aktis Oncology, Inc.
18.15 USD
1.01B USD
VOR
VOR • United States
Vor Biopharma Inc.
19.9 USD
1.08B USD 1Y -42.7%
PROK
PROK • United States
ProKidney Corp.
1.74 USD
694.58M USD 1Y -49.1%
AVLN
AVLN • United States
Avalyn Pharma Inc.
25.76 USD
1.14B USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
100.8% p.a.
Max Drawdown (5Y)
-99.1%
Sharpe Ratio (5Y)
-0.53
Beta Factor
1.79
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
High market risk: Beta of 1.79 indicates above-average volatility compared to the broader market.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (100.8% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -99.1% in the extended horizon.
ende